Alec Baldwin has quit Twitter again after causing controversy by commenting on Gillian Anderson's changing accent.
Alec Baldwin has quit Twitter again after causing controversy by commenting on Gillian Anderson's changing accent.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria.
U.S. stock index futures were subdued on Thursday as investors assessed earnings from companies, including Southwest Airlines and AT&T, while awaiting weekly jobless claims data for clues on the pace of recovery in the U.S. labor market. Shares of AT&T Inc gained 1% in premarket trading after the company's wireless subscriber additions trounced analysts' estimates. Southwest Airlines Co posted a smaller-than-expected quarterly adjusted loss and forecast lower cash burn in the second quarter.
The "Labeling and Product Decoration Annual Review 2021" report has been added to ResearchAndMarkets.com's offering.
Last week the BBC announced it has also commissioned series 12 and 13 of the drama.
The "Healthcare Facilities Management - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Health Minister Robin Swann expressed concern the Northern Ireland Protocol could hit the supply of medicines and medical devices to the region.
Labour has demanded an urgent investigation into the prime minister’s conduct.
The company said consumers were snapping up Nespresso pods, Nescafe instant coffee and Starbucks-branded products as sales grew 7.7% on an organic basis - higher than analysts had forecast.
SCANFIL PLC STOCK EXCHANGE RELEASE 22 APRIL 2021 2.15 P.M.Scanfil’s programme to repurchase its own shares has been completed on 22 April 2021. The shares were acquired at the market price quoted at the time of the repurchase in public trading on Nasdaq Helsinki Ltd. Own shares were used and will be used to fulfil obligations related to the option scheme to key personnel. The share repurchase was based on an authorisation granted by the Annual General Meeting on 23 April 2020, that authorised the Board of Directors to decide on a repurchase of a maximum of 5,000,000 own shares. Based on the authorisation the Board of Directors decided on 24 April 2020 to continue a share repurchase programme started on 9 March 2020, on the basis of the authorisation granted by the Annual General Meeting on 24 April 2019. The Board of Directors’ decision on 24 April 2020 specified the programme to finish at the latest at the next Annual General Meeting. In the programme the number of repurchase shares was defined at the maximum of 300,000 shares, which accounted for approximately 0.5 % of all shares of the Company. The maximum amount of money used in the repurchase was EUR 1.4 million. According to the programme own shares were repurchased in two periods: 9 March 2020 – 22 April 2020 (154,691 shares) and 24 April 2020 – 22 April 2021 (24,047 shares). In total, 178,738 own shares were acquired and EUR 705,776.08 was used in the programme.After completing the programme Scanfil plc holds a total of 198,738 own shares which is equivalent to approximately 0.3 per cent of all shares of the Company. Scanfil plcPetteri Jokitalo CEOtel. +358 8 4882 111 Scanfil is an international manufacturing partner and system supplier for the electronics industry with 40 years of experience in demanding manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability. Typical Scanfil products are modules or integrated products for e.g. self-service application, automation systems, wireless connectivity modules, climate control systems, collection and shorting systems, analysers and environmental measurement solutions. Scanfil services are used by numerous international automation, safety, energy, cleantech, connectivity and health service providers, as well as companies operating in the field of urbanisation. Scanfil’s network of factories consists of 10 production units in Europe, Asia and North America.
If you ask a dozen experts who has the best 5G network in the United States right now, you might not be able to find a discernible winner between AT&T (NYSE: T), T-Mobile US (NASDAQ: TMUS), and Verizon (NYSE: VZ). RootMetrics said AT&T has the best 5G network based on superior download speeds and reliability. Ookla said T-Mobile's speeds are best right now and its customers can connect to its 5G network more often.
'Chimera' creatures with human organs could be medically useful – but can we really treat them like other animals?
Il Friuli Venezia Giulia verso la zona gialla -con nuove regole per spostamenti e riaperture per scuola, ristoranti e bar- in base ai dati covid e al calo dell'indice Rt. "Il report inviato nella notte dall'Istituto superiore di sanità, che sarà ufficializzato a breve, evidenzia che i contagi in Friuli Venezia Giulia sono scesi con un indice Rt passa da 0,72 a 0,61 e, per prima volta, dall'inizio della terza ondata i livelli di occupazione dei posti letti nei reparti di terapia intensiva e nelle aree mediche sono sotto la soglia di guardia. Inoltre, procede l'attività di monitoraggio sulle mutazioni del virus e, su questo fronte, la situazione appare sotto controllo. Dati che dovrebbero permettere l'inquadramento della nostra regione in zona gialla", dice il vicegovernatore del Friuli Venezia Giulia con delega alla Salute, Riccardo Riccardi, durante la riunione di questa mattina con l'Ufficio scolastico regionale e i sindacati della scuola. Analizzando l'andamento della campagna vaccinale Riccardi ha spiegato che "le somministrazioni procedono a pieno ritmo. Il nostro sistema sanitario è in grado di rispettare l'obiettivo delle 10mila inoculazioni indicato dal generale Figliuolo, ma siamo vincolati dalla disponibilità dei vaccini e dall'andamento dei flussi di consegna, quindi l'auspicio è che arrivino presto ulteriori dosi". "In Friuli Venezia Giulia il 23% della popolazione residente - ha aggiunto - ha ricevuto il vaccino, ma attendiamo di capire quali decisioni saranno adottate dal commissario Figliuolo in merito all'estensione della campagna vaccinale. A causa dei cambiamenti di rotta sulla somministrazione del vaccino Astrazeneca, solo prendendo in considerazione il comparto scolastico che rappresenta un tassello importante del quadro complessivo, nella nostra regione ci sono infatti 1.800 persone che attendono di essere vaccinate".
(Bloomberg) -- Credit Suisse Group AG is raising $2 billion from investors and cutting the hedge fund unit at the center of the Archegos Capital Management losses as Chief Executive Officer Thomas Gottstein seeks to recover from one of the most turbulent periods in the bank’s recent history.Credit Suisse, which has exited about 97% of its exposure to Archegos, expects a related 600 million-franc ($654 million) loss in the second quarter, taking its total hit from the collapse to about $5.5 billion. In response, its cutting about a third of its exposure in the prime business catering to hedge fund clients, while strengthening capital with the sale of notes converting into shares.Gottstein is battling to rescue his short tenure as chief executive officer after Credit Suisse was hit harder than any other competitor by the collapse of Archegos, the family office of U.S. investor Bill Hwang. The timing of the blowup could hardly have been worse, coming just weeks after Credit Suisse found itself at the center of the Greensill Capital scandal, when it was forced to suspend investment funds. While seeking to placate investors hurt by the losses, he also now faces the fresh challenge of navigating enforcement proceedings announced by Swiss regulator Finma on Thursday.The double whammy wiped out a year of profit and left Gottstein fighting to demonstrate to incoming Chairman Antonio Horta-Osorio that he’s of the right mettle to carry the bank through the volatility which has left investors nursing losses and questioning its strategy and controls. Having taken on the position more than a year ago, the CEO had stumbled over other hits before Greensill shattered what was supposed to be a new era of calm.The two scandals have left the CEO standing while many once powerful members of his management board had to leave. Gone are investment banking head Brian Chin and Chief Risk Officer Lara Warner, along with a raft of other senior executives including equities head Paul Galietto and the co-heads of the prime brokerage business. Asset management head Eric Varvel is also being replaced in that role by ex-UBS Group AG veteran Ulrich Koerner.The bank has also suspended its share buyback and cut the dividend.Credit Suisse fell as much as 6.9% in Zurich trading and was 6.1% lower as of 11:19 a.m. local time, taking this year’s losses to about 23%.The bank plans to reduce risk at the investment bank, including cutting about $35 billion of leverage exposure at the prime brokerage unit -- which services its hedge fund clients, Gottstein said in an interview with Bloomberg Television. That’s about a third of its total exposure.“Although capital has been mainly addressed, we still see questions remaining in terms of strategy and risk management,” JPMorgan Chase & Co. analysts wrote in a note to investors. “Capital has been clearly the main focus.”The bank said the convertibles notes were sold to core shareholders, institutional investors and high net worth individuals and will help bring the bank’s CET1 ratio -- a key metric for capital -- nearer its target 13%. That number had dropped to 12.2% at the end of the first quarter.In addition to the enforcement proceedings, Credit Suisse said that the Swiss regulator has told it to hold more capital to guard against losses by taking a more conservative view of its risk. The bank increased its assets weighted according to risk for both Archegos and Greensill. While the capital raise came after Finma raised the bank’s capital requirements, Gottstein said the decision was the bank’s own.“This was not as a reaction to any request by Finma or any other regulator,” Gottstein said on a call with analysts. “It was our proactive view that, together with the board, we decided to issue these two mandatories and that will really help us also against any possible market weakness over the coming months.”The Greensill debacle is also far from over. Credit Suisse has so far returned about half the $10 billion in investor money held by the funds at the time of their suspension. While the bank marketed the funds as among the safest investments it offered, investors are left facing the prospect of steep losses as the assets are liquidated. Credit Suisse is leaning toward letting clients take the hit of expected losses in the funds, a person familiar with the discussions said earlier this month.“We have good visibility for a large portion of the remaining positions,” Gottstein said. “There are three more distinct positions which we will work through in the next months and quarters. We are not planning to do any form of step-in. We are very clearly focused on getting the cash back to our investors.”The impact for Credit Suisse from both Archegos and Greensill could add up to $8.7 billion, according to JPMorgan analysts Kian Abouhossein and Amit Ranjan.First Quarter Highlights:International wealth management pretax profit 523m francs vs 442m estimateCET1 ratio 12.2% vs 12.1% estimateProvisions for credit losses 4.4b francsNet revenue 7.6b francsSwiss Universal Bank pretax profit 665m francs vs 548m estimateAPAC pretax profit 524m francs vs 304m estimate(Adds Gottstein comment on capital raise in 12th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
INTRODUCTION Medical researchers first began evaluating mRNA as a therapeutic modality in the 1990s. The clinical use of mRNA is presently being evaluated in both therapeutic (protein replacement therapies, and as an alternative to classical gene therapies) and preventive (mRNA vaccines) roles.New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "mRNA Therapeutics and Vaccines Market, 2020-2030" - https://www.reportlinker.com/p06064690/?utm_source=GNW There are over 65 mRNA therapeutics and more than 85 vaccines currently in the development pipeline. As a biomolecule, mRNA is well tolerated in vivo, and (depending on the encoded protein) is capable of inducing humoral and cell-mediated immune responses. Moreover, using this approach, researchers have demonstrated that it is possible to deliver adequate amounts of tumor antigens (bearing patient-specific molecular signatures), and provide the necessary costimulatory signals to mount an effective anticancer immune response. As indicated earlier, mRNA-based interventions are also being evaluated as protein replacement therapies and alternatives to classical gene therapies; however, research on the aforementioned modalities is still in its infancy, with several potential leads in the preclinical stages. Such therapies are predominantly being developed for treating rare disorders. On the other hand, using mRNA, it is possible to develop both personalized (for various cancer) and general-use vaccines (for infectious diseases). Interestingly, mRNA vaccines have shorter development and manufacturing timelines, compared to their traditional counterparts. In fact, Pfizer and BioNtech’s recently approved vaccine (BNT-162) and Moderna’s late phase candidate (mRNA-1273) against the novel coronavirus strain, are both mRNA-based preventive solutions.Despite the potential benefits, there are, however, several challenges that limit the use of mRNA as a therapeutic. One of the major concerns is related to the short cytoplasmic half-life of the molecule, which compromises its efficacy as a therapeutic / vaccine. Other known setbacks of using mRNA as a therapy include its large size and inherent antigenicity, which complicate therapy administration and immune tolerance, respectively. Over the years, manipulation of the chemical structure of mRNA has enabled medical researchers and therapy developers to address some of the aforementioned challenges. Similarly, with regards to therapy delivery, lipoplexes and lipid-based nanoparticles are now preferred vehicles (among other contemporary nucleic acid delivery methods) for the targeted, intracellular delivery of therapeutic mRNA. However, companies (mostly startups and small firms) engaged in this field still claim to be in pursuit of better drug delivery strategies. In the last five years alone, close to USD 8 billion has been invested into companies that are engaged in developing mRNA-based therapeutics and vaccines; a significant proportion of the capital has come from public sector investors / state-backed institutes. Further, over the last few years, there has been noticeable consolidation, with stakeholders entering into strategic partnerships to support ongoing R&D initiatives. In the foreseen future, as more mRNA-based therapeutic / vaccine leads demonstrate proof-of-concept, enter into clinical testing and are eventually marketed, the opportunity for stakeholders engaged in this niche industry segment is anticipated to witness substantial growth.SCOPE OF THE REPORTThe “mRNA Therapeutics and Vaccines Market, 2020-2030” report features an extensive study of the current market landscape and future potential of the players engaged in the development of mRNA-based therapeutics and vaccines for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features: A detailed assessment of the current market landscape of mRNA therapeutics and vaccines, along with information on type of product candidate, phase of development, type of development program, type of delivery vehicle, target disease indication, target therapeutic area and route of administration. It also includes details related to year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. Further, it presents an elaborate analysis of the contemporary trends, presented using two schematic representations, including [A] logo landscape, highlighting the distribution of drug developers based on company size and location of their headquarters, and [B] grid analysis, presenting the distribution of drugs based on target disease indication, type of development program and type of candidate. It also provides a detailed analysis of key therapeutic areas, such as oncological disorders and infectious diseases, for which mRNA-based therapeutics and vaccines are being developed. A competitiveness analysis of key players engaged in this domain. The analysis is presented in the form of spider web representations, which take into consideration several important parameters, such as number of early stage candidates, number of late stage candidates, number of deals signed, amount raised through funding, company size (in terms of number of employees) and years of experience in the industry. Detailed profiles of drug candidates that are in advanced stages of development. Each profile features an overview of the drug and respective developer, details related to type of candidate, route of administration, phase of development, target disease indication and therapeutic area, mechanism of action, technology used, and recent developments (including information of partnerships, clinical trials and results and special review designations awarded). An analysis of the completed, ongoing and planned clinical studies for mRNA therapeutics and vaccines. The trials considered in the analysis were analyzed on the basis of various relevant parameters, such as trial registration year, trial recruitment status, number of patients enrolled, study design, target patient segment, trial focus area, target therapeutic area, geographical location of trials and leading organizations. An in-depth analysis of the various patents that have been filed / granted related to mRNA delivery technologies / methods, since 2017. The analysis also highlights the key parameters associated with the patents, including information on patent application year, patent publication year, geographical location / patent jurisdiction, IPCR symbols, emerging focus areas and leading players. In addition, it includes detailed patent benchmarking analysis based on leading players. Further, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. An analysis of the partnerships that have been inked by stakeholders engaged in the development of mRNA-based therapeutics and vaccines, during the period 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements, and other relevant types of deals. An analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies that are engaged in the development of mRNA-based therapeutics and vaccines A discussion on the affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.One of the key objectives of the report was to estimate the existing market size and the future growth potential within the mRNA therapeutics and vaccines market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (infectious diseases and oncological disorders), [B] route of administration (intravenous and intramuscular) and [D] key geographical regions (North America, Europe, Asia Pacific, MENA and LATAM regions). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts’ viewsWhile the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.KEY QUESTIONS ANSWERED Who are the leading players engaged in the development of mRNA therapeutics and vaccines? Which key clinical conditions can be treated by mRNA drugs? What are the investment trends in this industry? Which partnership models are commonly adopted by stakeholders engaged in this domain? Which regions have emerged as the key hubs for conducting clinical studies focused on mRNA drugs? How has the intellectual property landscape in this market evolved over the years? Which factors are likely to influence the evolution of this market? How is the current and future market opportunity likely to be distributed across key market segments?CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the mRNA therapeutics and vaccines market and its likely evolution in the short-mid term and long term.Chapter 3 provides a general overview of mRNA therapeutics and vaccines, including information on the advantages of these novel biological entities and their historical evolution. The chapter lays emphasis on the application areas of mRNA drugs. Further, it includes information on delivery routes and vehicles for the transfer of mRNA drugs in the body. It also includes a discussion on the various challenges associated with their therapeutic use.Chapter 4 presents a detailed assessment of the current market landscape of mRNA therapeutics and vaccines, along with information on type of product candidate, phase of development, type of development program, type of delivery vehicle, target disease indication, target therapeutic area and route of administration. It also includes details related to year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. Further, it presents an elaborate analysis of the contemporary trends, presented using two schematic representations, including [A] logo landscape, highlighting the distribution of drug developers based on company size and location of their headquarters, and [B] grid analysis, presenting the distribution of drugs based on target disease indication, type of development program and type of candidate. It also provides an in-depth analysis of key therapeutic areas, such as oncological disorders, infectious diseases for which mRNA based therapeutics and vaccines are being developed.Chapter 5 includes a competitiveness analysis of key players engaged in this domain. The analysis is presented in the form of spider web representations, which take into consideration several important parameters, such as number of early stage candidates, number of late stage candidates, number of deals signed, amount raised through funding, company size (in terms of number of employees) and years of experience in the industry.Chapter 6 consists of detailed profiles of drug candidates that are in advanced stages of development. Each profile features an overview of the drug and respective developer, details related to type of candidate, route of administration, phase of development, target disease indication and therapeutic area, mechanism of action, technology used, and recent developments (including information of partnerships, clinical trials and results and special review designations awarded).Chapter 7 features an analysis of the completed, ongoing and planned clinical studies for mRNA therapeutics and vaccines. The trials considered in the analysis were analyzed on the basis of various relevant parameters, such as trial registration year, trial recruitment status, number of patients enrolled, study design, target patient segment, trial focus area, target therapeutic area, geographical location of trials and leading organizations.Chapter 8 An in-depth analysis of the various patents that have been filed / granted related to mRNA delivery technologies / methods, since 2017. The analysis also highlights the key parameters associated with the patents, including information on patent application year, patent publication year, geographical location / patent jurisdiction, IPCR symbols, emerging focus areas and leading players. In addition, it includes detailed patent benchmarking analysis based on leading players. Further, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.Chapter 9 includes detailed assessment of the partnerships that have been inked by stakeholders engaged in the development of mRNA-based therapeutics and vaccines, during the period 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements, and other relevant types of deals.Chapter 10 provides insights on the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies that are engaged in the development of mRNA-based therapeutics and vaccines.Chapter 11 presents a detailed analysis of the current and forecasted opportunity across [A] key therapeutic areas (infectious diseases and oncological disorders), [B] route of administration (intravenous and intramuscular) and [D] key geographical regions (North America, Europe, Asia Pacific, MENA and LATAM regions). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.Chapter 12 includes a discussion on the affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.Chapter 13 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic formatChapter 14 presents an insightful discussion on the views presented by various industry experts present across the globe, on YouTube. The summary of insights provided by each expert is discussed across focus area, current industry status / challenges and future outlook.Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.Chapter 16 is an appendix, which provides list of companies and organizations highlighted in this report.Read the full report: https://www.reportlinker.com/p06064690/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The "Cement Global Market Review 2021 and Forecast to 2030 (with COVID-19 Impact Estimation)" report has been added to ResearchAndMarkets.com's offering.
Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "Insurance Analytics Market by Component (Tools and Services), Application (Claims Management, Risk Management, Customer Management and Personalization, Process Optimization), Deployment Mode, Organization Size, End User, and Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global insurance analytics market size is projected to grow from USD 8.8 billion in 2020 to USD 20.6 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 15.1% during the forecast period. Several insurance providers are accelerating investments in digitization and closing gaps in business continuity models. The integration of third-party data to mitigate risk is increasing in urgency. Throughout this time, customers are reminded of how significant the role of insurance is in their lives. For example, health coverage assists with drug and treatment plans for the ill, employment insurance helps those impacted by the economic turmoil, and business interruption coverage supports businesses unable to operate. Companies must continue investing and enabling access for customers while ensuring underwriters are well-informed of upcoming risks. Emergencies, such as COVID-19, highlight the need for insurers to seamlessly integrate reliable data sources, actionable insights, and responsive control measures to help navigate the uncertain landscape. By leveraging data and investing in digitization and analytics, insurers can navigate this challenging period and move the industry forward. Process Optimization: The fastest-growing segment of the insurance analytics market, by application. Based on application, the insurance analytics market is bifurcated into claims management, risk management, customer management and personalization, process optimization, and others (workforce management and fraud detection). Insurers are widely using analytics solutions to understand the potential risks and deploy countermeasures to mitigate losses, or at least screen, pre-empt, and assess the cost of risks in the underwriting process. Risk management involves the identification, assessment, and management of potential risks, incorporating analytics to support decision-making by clearly stating business goals and objectives, and facilitating precise information management with a better understanding of the trade-offs between risks and rewards. Risk management provides insurers with the risk capacity to maintain specific credit ratings, manage capital, and reduce earnings volatility across insurance companies. Insurance Companies: The largest growing end-user segment of the insurance analytics market. Insurance companies are the end-user companies that provide various types of insurance, such as consumer insurance (including life and health insurance, and vehicle/auto insurance) and commercial insurance (employee insurance and asset insurance for manufacturing companies). Insurance companies are now widely adopting various technology solutions, including analytics, for their internal and customer-facing services. For example, multi-line carriers that supply consumer policies - for homes, cars, and small groups - in addition to business services, such as P&C insurance, run several applications to handle underwriting, claims, and Customer Relationship Management (CRM). Increasing service demand coupled with critical end-of-year fiscal reporting forces these organizations to adopt advanced technological solutions, leading to a larger market size during the forecast period. Bajaj Allianz Life Insurance, a Pune, India-based life insurance provider, is among the leading insurers in India who are using predictive analytics across their insurance operations. The company is leveraging predictive analytics across its customer life cycle to assess customer risk, to determine the potential of a customer to renew or lapse a policy, and to act accordingly. Risk management, fraud detection, customer management, and personalization are some of the key application areas where the India-based insurer is applying analytics to improve operational efficiency, reduce cost, and enrich customer experience. APAC: The fastest growing region in the insurance analytics market. The growing digitalization across the APAC region to deal with a massive amount of data would drive the adoption of insurance analytics platforms in the region. APAC has witnessed advanced and dynamic adoption of new technologies and is expected to record the highest CAGR during the forecast period. BRIDGEi2i is one such company that offers user-focused insurance analytics solutions and which has continued to record growth in APAC. The company has achieved one of the leading positions in the insurance analytics market due to its well-practiced strategy of expanding its customer base through acquisitions as well as partnerships with significant players in the market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights4.1 Attractive Opportunities in the Insurance Analytics Market4.2 Market: Top Three End-users4.3 Market, by Region4.4 North American Market, by Component and End-user 5 Market Overview and Industry Trends5.1 Introduction5.2 Market Dynamics5.2.1 Drivers18.104.22.168 Rising Need of Big Data and Predictive Modeling Capability During the COVID-19 Pandemic Drives the Adoption of Insurance Analytics Solutions22.214.171.124 Rise in Adoption of IoT Products5.2.2 Restraints126.96.36.199 Rising Cyberattacks and Their Threats188.8.131.52 Difficulty to Integrate Insurance Platforms with Legacy Systems5.2.3 Opportunities184.108.40.206 COVID-19 Accelerated Organizations to New Customer Engagement Through Digital Experiences220.127.116.11 Need for Cloud-Based Digital Solutions by Insurer to Obtain Higher Scalability5.2.4 Challenges18.104.22.168 Data Security and Privacy Concerns5.2.5 Cumulative Growth Analysis5.3 Insurance Analytics Market: Ecosystem5.4 Case Study Analysis5.4.1 Cnseg and Fenseg Uses Sas Insurance Analytics to Eliminate Insurance Fraud and Boost Accuracy5.4.2 Farmers Insurance Group Uses Salesforce Einstein Analytics to Streamline Processes5.4.3 Die Mobilier Insurance Accelerates Operational Data Analytics with Oracle Database In-Memory5.4.4 Great American Insurance Group Embraced Pega Customer Service to Eliminate Complexities and Deliver Exceptional Customer Experience5.4.5 Promutuel Insurance Embraced Guidewire to Transform Its Claims Business5.4.6 Ydrogios Insurance Choose Sas Detection and Investigation of Insurance to Reduce Costs5.5 Insurance Analytics Market: COVID-19 Impact5.6 Patent Analysis5.6.1 Methodology5.6.2 Document Type5.6.3 Innovation and Patent Applications22.214.171.124 Top Applicants5.7 Value Chain Analysis5.8 Technology Analysis5.8.1 5G and Insurance Analytics5.8.2 AI and Insurance Analytics5.8.3 IoT and Insurance Analytics5.9 Porter's Five Force Analysis5.9.1 Threat of New Entrants5.9.2 Threat of Substitutes5.9.3 Bargaining Power of Suppliers5.9.4 Bargaining Power of Buyers5.9.5 Intensity of Competitive Rivalry 6 Insurance Analytics Market, by Component6.1 Introduction6.1.1 Components: Market Drivers6.1.2 Components: COVID-19 Impact6.2 Tools6.3 Services6.3.1 Managed Services6.3.2 Professional Services126.96.36.199 Consulting188.8.131.52 Support and Maintenance184.108.40.206 Deployment and Integration 7 Insurance Analytics Market, Application7.1 Introduction7.1.1 Applications: Market Drivers7.1.2 Applications: COVID-19 Impact7.2 Claims Management7.3 Risk Management7.4 Customer Management and Personalization7.5 Process Optimization7.6 Others 8 Insurance Analytics Market, by Deployment Mode8.1 Introduction8.1.1 Deployment Modes: Market Drivers8.1.2 Deployment Modes: COVID-19 Impact8.2 On-Premises8.3 Cloud 9 Insurance Analytics Market, by Organization Size9.1 Introduction9.1.1 Organization Size: Market Drivers9.1.2 Organization Size: COVID-19 Impact9.2 Large Enterprises9.3 Small and Medium-Sized Enterprises 10 Insurance Analytics Market, by End-user10.1 Introduction10.1.1 End-users: Market Drivers10.1.2 End-users: COVID-19 Impact10.2 Insurance Companies10.3 Government Agencies10.4 Third-Party Administrators, Brokers, and Consultancies 11 Insurance Analytics Market, by Region11.1 Introduction11.2 North America11.3 Europe11.4 Asia-Pacific11.5 Middle East and Africa11.6 Latin America 12 Competitive Landscape12.1 Overview12.2 Market Evaluation Framework12.3 Market Share, 202012.4 Historical Revenue Analysis of Key Market Players12.5 Ranking of Key Market Players in Market, 202012.6 Company Product Footprint Analysis12.7 Competitive Scenario12.7.1 New Product Launches and Product Enhancements12.7.2 Business Expansions12.7.3 Mergers and Acquisitions12.7.4 Partnerships, Agreements, Contracts, and Collaborations12.8 Company Evaluation Matrix Definitions and Methodology12.8.1 Star12.8.2 Emerging Leaders12.8.3 Pervasive12.8.4 Participants12.8.5 Strength of Product Portfolio (Global)12.8.6 Business Strategy Excellence (Global)12.9 Startup/SME Evaluation Matrix, 202012.9.1 Progressive Companies12.9.2 Responsive Companies12.9.3 Dynamic Companies12.9.4 Starting Blocks12.9.5 Strength of Product Portfolio (Startup/SME)12.9.6 Business Strategy Excellence (Startup/SME) 13 Company Profiles13.1 Introduction13.2 IBM13.3 Salesforce13.4 Oracle13.5 Microsoft13.6 Opentext13.7 Sap13.8 Verisk Analytics13.9 Sas Institute13.10 Vertafore13.11 Tibco13.12 Qlik13.13 Sapiens13.14 Board International13.15 Bridgei2I13.16 Microstrategy13.17 Guidewire Software13.18 Lexisnexis Risk Solutions13.19 WNS13.20 Hexaware Technologies13.21 Pegasystems13.22 Applied Systems13.23 Insuredmine13.24 Refocus AI13.25 Riskville13.26 Pentation Analytics13.27 Habit Analytics13.28 Artivatic.AI13.29 Cybercube13.30 Arceo.AI 14 Adjacent and Related Markets14.1 Introduction14.2 Digital Insurance Market - Global Forecast to 202114.2.1 Market Definition14.2.2 Market Overview220.127.116.11 Digital Insurance Market, by Component18.104.22.168 Digital Insurance Market, by Service22.214.171.124 Digital Insurance Market, by End-user126.96.36.199 Digital Insurance Market, by Insurance Application188.8.131.52 Digital Insurance Market, by Deployment Mode184.108.40.206 Digital Insurance Market, by Organization Size220.127.116.11 Digital Insurance Market, by Region14.3 AI in Fintech Market - Global Forecast to 202514.3.1 Market Definition14.3.2 Market Overview18.104.22.168 AI in Fintech Market, by Solution22.214.171.124 AI in Fintech Market, by Service126.96.36.199 AI in Fintech Market, by Deployment Mode188.8.131.52 Mobile Uc&C Market, by Application Area184.108.40.206 AI in Fintech Market, by Region 15 Appendix15.1 Industry Experts15.2 Discussion Guide15.3 Knowledge Store: Subscription Portal15.4 Available Customizations For more information about this report visit https://www.researchandmarkets.com/r/5l05lp CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Mikel Arteta reveals Kroenkes have apologised to him over Super League
The Gunners are looking to leapfrog the Toffees and reach eighth place in the Premier League table.
Sammy Kimmence faces jail time for the crime.
'Full Time' aims to help combat child food poverty with healthy and affordable recipes.